233 related articles for article (PubMed ID: 18034591)
1. Defining the role of insulin detemir in Basal insulin therapy.
Morales J
Drugs; 2007; 67(17):2557-84. PubMed ID: 18034591
[TBL] [Abstract][Full Text] [Related]
2. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.
Chapman TM; Perry CM
Drugs; 2004; 64(22):2577-95. PubMed ID: 15516157
[TBL] [Abstract][Full Text] [Related]
3. Insulin detemir: a review of its use in the management of diabetes mellitus.
Keating GM
Drugs; 2012 Dec; 72(17):2255-87. PubMed ID: 23110609
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
Chapman TM; Perry CM
BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219
[TBL] [Abstract][Full Text] [Related]
5. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
[TBL] [Abstract][Full Text] [Related]
6. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.
Laubner K; Molz K; Kerner W; Karges W; Lang W; Dapp A; Schütt M; Best F; Seufert J; Holl RW
Diabetes Metab Res Rev; 2014 Jul; 30(5):395-404. PubMed ID: 24302583
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
Bartley PC; Bogoev M; Larsen J; Philotheou A
Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.
Valentine WJ; Palmer AJ; Erny-Albrecht KM; Ray JA; Cobden D; Foos V; Lurati FM; Roze S
Adv Ther; 2006; 23(2):191-207. PubMed ID: 16751153
[TBL] [Abstract][Full Text] [Related]
9. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus.
McKeage K; Goa KL
Drugs; 2001; 61(11):1599-624. PubMed ID: 11577797
[TBL] [Abstract][Full Text] [Related]
10. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
Valensi P; Cosson E
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
[TBL] [Abstract][Full Text] [Related]
11. Insulin detemir: a long-acting insulin product.
Jones MC; Patel M
Am J Health Syst Pharm; 2006 Dec; 63(24):2466-72. PubMed ID: 17158694
[TBL] [Abstract][Full Text] [Related]
12. Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
Swinnen SG; Simon AC; Holleman F; Hoekstra JB; Devries JH
Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD006383. PubMed ID: 21735405
[TBL] [Abstract][Full Text] [Related]
13. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis.
Tricco AC; Ashoor HM; Antony J; Beyene J; Veroniki AA; Isaranuwatchai W; Harrington A; Wilson C; Tsouros S; Soobiah C; Yu CH; Hutton B; Hoch JS; Hemmelgarn BR; Moher D; Majumdar SR; Straus SE
BMJ; 2014 Oct; 349():g5459. PubMed ID: 25274009
[TBL] [Abstract][Full Text] [Related]
14. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
15. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
Raslova K
Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842
[TBL] [Abstract][Full Text] [Related]
16. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.
Frier BM; Russell-Jones D; Heise T
Diabetes Obes Metab; 2013 Nov; 15(11):978-86. PubMed ID: 23551900
[TBL] [Abstract][Full Text] [Related]
17. [Insulin detemir (Levemir)].
Scheen AJ; Radermecker RP; Philips JC; Paquot N
Rev Med Liege; 2005 Oct; 60(10):814-9. PubMed ID: 16358671
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on insulin glargine in type 1 and 2 diabetes mellitus.
McKeage K; Goa KL
Treat Endocrinol; 2002; 1(1):55-8. PubMed ID: 15765621
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
20. An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.
Fujii H; Watanabe Y; Ueki A; Ohno A; Kato M; Kondo K; Takamura H; Takesue M; Nishimura H; Matsuda D; Miyakawa T
Int J Clin Pract; 2010 Oct; 64(11):1512-1519. PubMed ID: 20678116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
